Special News: Gilead Sciences, Inc.(NASDAQ:GILD), Alcoa Inc (NYSE:AA) SBWire (press release) It demonstrated "highly statistically significant efficacy" in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Are investors worried about the recent updates with ... |
